AUGS Testimony for FDA Panel on Trans-vaginal Mesh for the Anterior Wall
Docket No. FDA-2018-N-4395 for “The Obstetrics and Gynecology Devices Panel of the Medical Devices Advisory Committee”

At the American Urogynecologic Society (AUGS), we respect the vital role of the FDA in providing our patients with safe medical devices that meet their health care needs. We also respect the FDA’s leadership over the past decade in pursuing this mandate within Urogynecology. The FDA’s early recognition of risks associated with trans-vaginal mesh, first identified in 2008, and then expanded in the 2011 FDA Safety Communication, were important counters to inadequacies in the scientific development and early regulation of these devices.[1] Moreover, the decision in January of 2016 to reclassify surgical mesh for trans-vaginal repair of pelvic organ prolapse as Class III, paved the way for the necessary premarket assessment of these devices. We are also honored to attend the Advisory Committee Meeting scheduled for February 12, 2019 to contribute to the evaluation of the benefits and risks associated with the mesh medical devices for anterior wall pelvic organ prolapse, towards defining the appropriate population of women for whom this is a reasonable option.

AUGS supports the continued availability of transvaginal mesh devices for the treatment of pelvic organ prolapse (POP). We acknowledge the safety concerns around these devices, and this document will lay out some of the programs and policies that we propose will maximize the safety for their use, and improve the availability of well-trained providers who can help them decide if or when to use them, and to more skilfully address the unintended outcomes associated with their use. AUGS feels that women are better served when there are more options for their treatment, and transvaginal mesh for prolapse is a very reasonable and possibly advantageous option for women to consider under certain conditions.

Indications for Trans-vaginal Mesh in POP Repairs

All surgical interventions offer benefit to the patient that must be balanced by the potential risk inherent to the intervention. The probability of benefit varies by procedure, patient, and surgeon, as does the type of complication and probability of a complication. In considering a potential treatment, patients should personally balance the probability of benefit with the potential risk of complications. Moreover, the evaluation of potential complications should not only consider the frequency of occurrence, but also the degree of associated morbidity, and the degree of difficulty of treating them. Providing adequate information to patients to prepare them for these decisions is a responsibility of the physician proposing treatment. Physicians can help to frame the benefits and risks through shared decision-making, but ultimately it is the patient that must make this decision.
Because the balance of benefit and risk is a personal decision, women benefit from having a range of treatment options. This is especially true of pelvic floor disorders, where the goal of intervention is to improve the quality of life of the patient. Different patients experience pelvic floor disorders differently, underlining the need for nonsurgical options, which may have decreased efficacy, but balanced against a lower risk of complication. The need for alternative treatments also applies to surgical interventions. Within the epidemiologic literature, the reported rate of reoperation for pelvic organ prolapse is 13% at five years, rising to 17% at ten years. [2,3] Not all patients with recurrence seek additional surgery, so the actual recurrence rate is probably higher. Importantly, the reoperation rate is higher for women who have previously failed a surgery for pelvic organ prolapse (17%) compared to those having their first surgery for POP (12%). [2] This population of women who have already failed a surgery for POP, especially if they are very symptomatic, are examples of patients who may be willing to assume higher risk of complication for a more durable surgical repair.

There are three main types of surgical procedures performed with surgical mesh to treat pelvic floor disorders:

- Trans-vaginal mesh to treat POP
- Trans-abdominal mesh to treat POP
- Mid-urethral mesh sling to treat SUI

Each of these procedures has unique profiles of benefit and risk, and it is important not to confuse the procedures and the benefits and risks. AUGS agrees with the FDA in the stated aim of this panel to consider the use of transvaginal mesh for the treatment of POP only, as the risks and benefits of mesh use in these three categories are substantially different.

The promise of the trans-vaginal mesh procedure, introduced in the early 2000s for POP, was to achieve the durability of an abdominal mesh procedure, with a less invasive surgical approach, and decrease in complications of the sacral colpopexy related to the abdominal approach. The FDA Safety Announcements in 2008 and 2011 demonstrated that the actual results of the trans-vaginal approach included higher complications than the native tissue repairs and the abdominal mesh repairs, with uncertain improvement in durability.[1] However, the outcomes were different depending on the vaginal compartment where the mesh was used. For example, adding mesh to repairs of the posterior vaginal wall increased complications with no improvement in anatomical results or relief of symptoms.[4] Based on this evidence, all of the manufactures ceased marketing trans-vaginal mesh kits for posterior vaginal wall prolapse.

The anterior vaginal wall is the area of greatest vulnerability for native tissue POP repairs. Multiple Randomized Clinical Trials assessing POP procedures using trans-
vaginal mesh in the anterior vaginal wall show anatomic benefit, with less evidence of subjective benefit. [4,5] Nevertheless, some patients may decide that the mesh-based complications associated with these procedures are outweighed by the added durability provided by the trans-vaginal mesh. While AUGS does not feel that there is evidence to support the routine use of trans-vaginal mesh for POP, there are certain patient characteristics that increase the potential benefit of the trans-vaginal mesh approach, creating a favourable balance with the increased rate of surgical complications. Specific characteristics include:

- Failed previous native tissue repairs
- Injury to the pelvic floor musculature
- Connective tissue or neurologic disorders, or other medical conditions that may increase the predicted rate of failure
- Medical or surgical issues compromising abdominal access
- Medical advantage for regional anaesthesia

Optimizing Evidence on the Use of Trans-vaginal Mesh in POP Repairs

While there is adequate data to determine that adding trans-vaginal mesh to a posterior vaginal wall repair for primary prolapse does not improve outcomes and increases complications[4], the evidence for procedures using trans-vaginal mesh to repair the anterior wall is less clear. There are several glaring gaps in the evidence. Firstly, many of the RCTs investigating mesh in the anterior compartment used devices or mesh materials that are no longer available; as material improvements (such as lighter weight, open pore architecture) have taken place, mesh performance has improved, so older data should be applied to newer materials with caution. Moreover, there is a paucity of studies to compare the efficacy and safety in different populations of women, including the risk factors outlined in the previous paragraph. This compromises the ability to compare potential benefits to risks in any given patient. Additionally, best practices and algorithms for categorizing and treating mesh complications have not been well developed, and are often the expert opinion of individual surgeons with variable amounts of experience. Lastly, much of the available data comes from academic centers that may not reflect the real world performance of these products.

Because the current literature does not meet the needs of patients, AUGS promotes the use of a registry for Quality Improvement that will provide valuable information in a real-world, real-time, longitudinal, and patient-based fashion. The AUGS Quality Improvement Registry (AQUIRE) was developed as a quality improvement registry that allows physicians to participate in the Merit-Based Incentive Payment System arm of the Quality Payment Program. As AQUIRE has evolved, its focus and goals have expanded. AQUIRE now aims to collect real-world evidence to drive quality improvement by bringing together urogynecologists, gynecologists, urologists, industry and government agencies, to answer important questions best addressed through broad registry participation and evidence-based medicine. Data collected in AQUIRE will include patient-reported outcomes, and will be available to multiple
stakeholders, including the FDA and device manufacturers, to meet regulatory and device surveillance requirements, and aid in the improvement of devices. Recognizing that all surgical interventions have complications, AUGS is expanding the registry to include a module dedicated to the management of surgical complications, including mesh complications. This will provide important information to build clinical algorithms to inform physicians on how best to manage these complications with consistency and the best data available. Ultimately, the AQUIRE registry will provide the data to expand physicians’ understanding of benefits and risks of specific treatments, including mesh-based treatments, within specific populations. This will allow AUGS to leverage physician education to enhance patient education and realize personalized management of pelvic floor disorders.

Education Needs Related to Trans-vaginal Mesh in POP Repairs

AUGS sees a number of specific educational needs, both for patients and their providers, related to trans-vaginal mesh repair for prolapse, and related pelvic floor issues. With respect to patients, they are served by having information about pelvic floor conditions, and treatment considerations that are as individualized as possible. We are actively engaged in the development and use of a shared-decision model that allows patients to choose treatment options aligned with their own values and preferences, guided by the best available data. AUGS has shared-decision grids under development for pelvic floor disorders and they will be valuable in helping patients and their physicians make informed decisions.

The primary role of AUGS as a purveyor of surgical education for health care providers is the development and maintenance of competencies in diagnosis and management of pelvic floor disorders. This includes non-surgical treatments, and surgical treatments, including those that use mesh and alternative procedures to support patient choice; AUGS believes that these options should be available for all patients, for any pelvic floor condition. It also extends to developing and promoting competencies in managing surgical complications, including those related to mesh. The noted variation in complications associated with trans-vaginal mesh in POP repairs suggests that there is a spectrum of competency with these procedures. This highlights the importance of improving education for surgeons learning these techniques. AUGS supports the role of professional organizations in developing and supporting surgical education for both learners and practicing physicians related to trans-vaginal mesh in POP repairs. Our educational mission supports lifetime learning by defining the curriculum for learners and ensuring quality continuing education to support practicing physicians.

AUGS supports the FDA framework for assessing the benefits and risks of the trans-vaginal mesh procedures for anterior vaginal wall POP within different populations of women suffering from anterior vaginal POP. [6] AUGS believes that women are best served when they have options from which to choose, and well-educated and experienced providers. The approach outlined above will better allow women to make
personalized treatment decisions based on evidence. However, it is essential to define medical device safety and appropriate regulation of devices to ensure patient safety. We believe that registries, like AQUIRE, are the most appropriate means to his end. Expanding the AQUIRE registry and using it to enhance patient and physician education are priorities for AUGS.

Finally, AUGS would like to reflect on the recent history, before marketed devices specifically for the placement of transvaginal mesh for prolapse were introduced to the FDA. A wide variety of surgeons, seeking to improve on the sometimes frustrating failure rate of native-tissue repairs, were fashioning their own mesh or graft implants in a wide variety of techniques. The variation in techniques compromised efforts to compare techniques, and track outcomes in any meaningful way. The use of registries, such as AUGS’ AQUIRE registry, allows for surgeon data, patient information, Unique Device Identifiers (UDIs) and patient reported outcomes to provide robust and meaningful real-world and real-time information. If mesh devices marketed for prolapse were to be removed, we would lose the ability to use Unique Device Identifiers it is likely that some surgeons would, in their advocacy for their patients, feel the need to return to practice of devising their own techniques, which would curtail our ability to perform device surveillance and benchmarking analyses. AUGS believes this would actually be a disservice to women with pelvic floor disorders, especially for those with native-tissue failures.

References


